We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

48 hedge funds and large institutions have $121M invested in Orchestra BioMed in 2021 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 7

0.24% more ownership

Funds ownership: 59.42% → 59.66% (+0.24%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2% less capital invested

Capital invested by funds: $124M → $121M (-$2.95M)

4% less funds holding

Funds holding: 50 → 48 (-2)

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Holders
48
Holders Change
-2
Holders Change %
-4%
% of All Funds
0.84%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
4
Increased
10
Reduced
7
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$2.2M
2
WAM
Weiss Asset Management
Massachusetts
+$1.14M
3
KPF
K2 Principal Fund
Ontario, Canada
+$987K
4
WRBC
W.R. Berkley Corp
Connecticut
+$976K
5
Marshall Wace
Marshall Wace
United Kingdom
+$790K

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$2.45M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.19M
3
LGM
Logos Global Management
California
-$1.02M
4
MS
Maven Securities
Jersey
-$912K
5
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$758K
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
26
Weiss Asset Management
Massachusetts
$1.15M +$1.14M +115,822 New
WRBC
27
W.R. Berkley Corp
Connecticut
$1.08M +$976K +98,910 +995%
PVI
28
Pura Vida Investments
New York
$1.05M -$16K -1,616 -1%
Millennium Management
29
Millennium Management
New York
$960K +$336K +34,004 +54%
Marshall Wace
30
Marshall Wace
United Kingdom
$792K +$790K +80,067 New
PMAM
31
Picton Mahoney Asset Management
Ontario, Canada
$777K – – –
SCM
32
Shaolin Capital Management
Florida
$495K – – –
TD Asset Management
33
TD Asset Management
Ontario, Canada
$458K – – –
MF
34
Magnetar Financial
Illinois
$402K +$64.1K +6,489 +19%
Alyeska Investment Group
35
Alyeska Investment Group
Illinois
$247K – – –
AC
36
Athanor Capital
New York
$215K -$157K -15,938 -42%
WAM
37
Wolverine Asset Management
Illinois
$214K +$45.7K +4,632 +27%
Nomura Holdings
38
Nomura Holdings
Japan
$152K – – –
BCM
39
Basso Capital Management
Connecticut
$104K +$104K +10,500 New
Geode Capital Management
40
Geode Capital Management
Massachusetts
$102K – – –
6CM
41
683 Capital Management
New York
$99K – – –
ACM
42
Altium Capital Management
New York
$99K – – –
RCM
43
Rivernorth Capital Management
Florida
$99K – – –
AA
44
Ancora Advisors
Ohio
$53K +$53.3K +5,400 New
HI
45
Harbour Investments
Wisconsin
$30K – – –
Morgan Stanley
46
Morgan Stanley
New York
$6K – – –
UBS Group
47
UBS Group
Switzerland
$5K -$5.82K -590 -52%
TRCT
48
Tower Research Capital (TRC)
New York
$1K -$5.38K -545 -79%
CAM
49
Cormorant Asset Management
Massachusetts
– -$2.45M -240,000 Closed
LGM
50
Logos Global Management
California
– -$1.02M -100,000 Closed
1
2
3

OBIO Hedge Fund Activity: Q3 2021 in Review

48 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q3 2021, worth a combined $121M — down 2.4% from $124M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of OBIO and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 10 added.

The largest buyer was D.E. Shaw & Co, adding an estimated $2.2M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $2.45M sold.

  • 48 institutional investors held Orchestra BioMed (OBIO) as of Q3 2021, down from 50 in Q2 2021.
  • Funds reported $121M of Orchestra BioMed stock for Q3 2021, down 2.4% quarter-over-quarter.
  • 4 funds opened new Orchestra BioMed positions in Q3 2021 and 6 closed out, a net change of -2 holders.
  • The largest Orchestra BioMed buyer in Q3 2021 was D.E. Shaw & Co, an estimated $2.2M added.
  • The largest Orchestra BioMed seller in Q3 2021 was Cormorant Asset Management, an estimated $2.45M sold.

Based on aggregated 13F filings for Q3 2021.